Stock comparison
Evotec SE
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EVO
Evotec SE
Market cap
$1.08B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EVO | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 16F | 67B | HRMY |
| Benjamin Graham | 24F | 60C | HRMY |
| Philip Fisher | 22F | 75B | HRMY |
| Peter Lynch | 14F | 62C | HRMY |
| Joel Greenblatt | 0F | 28F | HRMY |
| Charlie Munger | 22F | 62C | HRMY |
| Terry Smith | 21F | 67B | HRMY |
Side-by-side metrics
| Metric | EVO | HRMY |
|---|---|---|
| Market cap | $1.08B | $1.75B |
| P/E (TTM) | - | 11.8x |
| EV/EBIT | - | 6.4x |
| ROIC (TTM) | -7.93% | 12.5% |
| Gross margin | 11.47% | 76.55% |
| Net margin | -26.02% | 16.2% |
| Revenue CAGR 5y | 5.21% | 29.85% |
| EPS CAGR 5y | - | 46.45% |
| Debt / Equity | 0.6x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EVO leads on
- EV/EBIT-vs 6.4x+195%
- P/E (TTM)-vs 11.8x+140%
HRMY leads on
- ROIC (TTM)12.5%vs -7.93%+163%
- Net margin16.2%vs -26.02%+162%
- Gross margin76.55%vs 11.47%+85%
- Revenue CAGR 5y29.85%vs 5.21%+83%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.